ERBB2 and gastroesophageal junction adenocarcinoma: Both the FDA and EMA have approved T-DXd in adult patients with locally advanced or metastatic HER2-positive gastric/GEJ adenocarcinoma who had received a trastuzumab-based regimen (US Food and Drug Administration, 2021; European Medicines Agency, 2021).